Sign in
EYPT Stock Price, Chart, Stats & News
EyePoint Pharmaceuticals, Inc.
Save
EyePoint Pharmaceuticals, Inc. (EYPT) does not currently pay a dividend.
278.35M
Market cap
–
Current P/E
6.16x
Forward P/E
EYPT chart
Fundamentals
Gross margin | 93.41% |
Operating margin | -775.96% |
Pretax margin | -738.50% |
Net margin | -739.39% |
Effective tax rate | 0.04% |
ROA | -63.73% |
ROE | -88.31% |
D/E | 0.07x |
Interest coverage ratio | – |
EYPT valuation
P/E | – |
P/S | 33.24x |
P/B | 3.39x |
P/CF | -4.32x |
P/FCF | -4.28x |
P/OCF | -4.32x |
PEG | 0.79x |
EV multiple | -4.69x |
About
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye.
Similar securities
Based on sector and market capitalization
Report issue